Company News

Cancer Genetics Selected for ReproCELL in a Multi-Year Agreement


Cancer Genetics, Inc. (CGI) announced its selection by Japanese regenerative medicine company, ReproCELL, Inc., to provide next-generation sequencing (NGS) based services and molecular information to enhance ReproCELLs translational medicine initiatives. Under the terms of the agreement, CGI will perform NGS using its recently launched Focus-Hotspot panel. This panel targets clinically actionable and validated mutations found in several of the most common solid tumors including breast, colorectal, and lung cancers. CGI expects to process several thousand samples over the next two years at the Companys genomic lab in Hyderabad, India to aid ReproCELL in advancing its product development portfolio.
Working with ReproCELL is a clear example of how genomic insights and regenerative medicine are coming together to transform drug discovery and healthcare.  This effort represents a major milestone for Cancer Genetics, and our India operation, as we continue to focus on its high-quality growth, and on partnering with companies in the region that can utilize our capabilities to accelerate our understanding of cancer, said Panna Sharma, CEO of Cancer Genetics.
ReproCELL, Inc. based in Yokohama, Japan, is a stem-cell technology based regenerative medicine, with operations in Asia, the United States, and Europe. It will be utilising the genomic information derived from CG Indias Focus-Hotspot panel to annotate tumor samples and develop a comprehensive database  of cancer mutational information to accelerate translational efforts.
Cancer Genetics NGS Focus-Hotspot panel will provide us with the capability and translational information to offer our partners access to the genomic insights that will improve the effectiveness of their development efforts, said Dr. Chikafumi Yokoyama, CEO at ReproCELL. Our position in next-generation drug discovery and regenerative medicine can be enhanced by focused translational initiatives that integrate genomic and molecular knowledge with our core technology.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top